author of the application is identified and that person's role in the project is identified. 20 points

4. *Organizational Experience.* The application identifies the qualifying experience of the organization to demonstrate the applicant's ability to effectively and efficiently administer this project. The application specifically identifies the applicant as a nationally-recognized organization, institution, or company with a record of study and analysis of rural and special transportation needs. Previous specific experience with work similar to the Tasks proposed is clearly and specifically described. The relationship between this project and other work planned, anticipated, or underway by the applicant is described, including a chart which lists all related Federal assistance received within the last five years. In the event a consortium of applicants is proposed, the project history of prior joint work should be provided. The previous Federal assistance is identified by project number, Federal agency, and grants or contracting officer. 25 points

Components of a Complete Application

A complete application consists of the following items in this order:

1. Application for Federal Assistance (Standard Form 424, REV 4–88);
2. Budget Information—Non-construction Programs (Standard Form 424A, REV 4–88);
3. Assurances—Non-construction Programs (Standard Form 424B, REV 4–88);
4. Table of Contents;
5. Budget justification for Section B—Budget Categories;
6. Proof of non-profit status, if appropriate;
7. Copy of the applicant's approved indirect cost rate agreement, if necessary;
8. Project Narrative Statement, organized in four sections addressing the following areas:
   (a) Understanding of the Effort,
   (b) Project Approach,
   (c) Staffing Utilization, Staff Background, and Experience
   (d) Organizational Experience;
9. Any appendices/attachments;
10. Certification Regarding Drug-Free Workplace;
11. Certification Regarding Debarment, Suspension and Other Responsibility Matters; and
12. Certification and, if necessary, Disclosure Regarding Lobbying.
13. Supplement to Section II—Key Personnel.
14. Application for Federal Assistance Checklist.

Dated: July 9, 1997.

David F. Garrison,

Principal Deputy Assistant Secretary for Planning and Evaluation.

[FR Doc. 97–18528 Filed 7–14–97; 8:45 am]

BILLING CODE 4151–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Amitav Hajra, University of Michigan: Based upon a report from the University of Michigan, information obtained by the Office of Research Integrity (ORI) during its oversight review, and Mr. Hajra's own admission, ORI found that Mr. Hajra, former graduate student, University of Michigan, engaged in scientific misconduct by falsifying and fabricating research data in five published research papers, two published review articles, one submitted but unpublished paper, in his doctoral dissertation, and in a submission to the GenBank computer data base. Mr. Hajra's doctoral training and research was supported by two Public Health Service (PHS) grants, and his experiments were conducted at and submitted for publication from the National Center for Human Genome Research, National Institutes of Health (NIH).

Specifically, Mr. Hajra fabricated and falsified original research in the following publications:

- Hajra, A., Collins, F.S. ''Structure of the leukemia-associated human CBFB gene.'' *Genomics* 26(3):571–579, 1995 (Retracted in *Genomics* 38(1):107, 1996);
- Hajra, A., Liu, P.P., Speck, N.A., Collins, F.S. ''Overexpression of core-binding factor α (CBFα) reverses cellular transformation by the CBFβ-smooth muscle myosin heavy chain chimeric oncoprotein.'' *Molecular and Cellular Biology* 15(9):4980–4989, 1995;
- Hajra, A., Liu, P.P., Wang, Q., Kelley, C.A., Stacy, T., Adelstein, R.S., Speck, N.A., and Collins, F.S. ''The leukemic core binding factor β-smooth muscle myosin heavy chain (CBFβ–SMMHC) chimeric protein requires both CBFβ and myosin heavy chain domains for transformation of NIH 3T3 cells.'' *Proc. Natl. Acad. Sci.* USA 92(6):1926–1930, 1995;
- Wijmenga, C., Gregory, P.E., Hajra, A., Schröck, E., Ried, T., Eils, R., Liu, P.P., and Collins, F.S. ''Core binding factor β-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.'' *Proc. Natl. Acad. Sci.* USA 93(4):1630–1635, 1996; and
- Liu, P.P., Wijmenga, C., Hajra, A., Blake, T.B., Kelley, C.A., Adelstein, R.S., Bagg, A., Rector, J., Cotelingham, J., Willman, C.L., and Collins, F.S. ''Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.'' *Genes, Chromosomes, and Cancer* 16:77–87, 1996 (Erratum in *Genes, Chromosomes, and Cancer* 18(1):71, 1997).

Mr. Hajra included fabricated and falsified data in the following review articles:

- Hajra, A., Liu, P.P., and Collins, F.S. ''Transforming properties of the leukemic Inv(16) fusion gene CBFB–MYH11.'' In Molecular Aspects of Myeloid Stem Cell Development in Current Topics in Microbiology and Immunology (L. Wolff and A.S. Perkins, Eds.) 211:289–298, 1996 (Review). Berlin and New York: Springer-Verlag; and
- Liu, P.P., Hajra, A., Wijmenga, C., and Collins, F.S. ''Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.'' *Blood* 85:2289–2302, 1995 (Review).

Mr. Hajra submitted a fabricated nucleotide sequence in computer data base entry U22149, ''Human leukemia-associated core binding factor subunit CBFbeta (CBFB) gene, promoter region and partial CDs.'' GenBank (NCBI, NLM, NIH), March 3, 1995 (withdrawn). He also fabricated the majority of data reported in his dissertation (Hajra, A. ''Transformation properties of the leukemic CBFβ–SMMHC chimeric protein.'' Dissertation, University of Michigan, Ann Arbor, MI, 1995), and he fabricated and falsified original research data in a submitted but unpublished manuscript (Hajra, A., Liu, P.P., Itoh, K., Kelley, C.A., Speck, N.A., Adelstein, R.S., and Collins, F.S. ''Myosin heavy chain properties necessary for cellular transformation by the leukemic CBFβ–SMMHC oncoprotein,'' submitted for publication to *Oncogene* on November 29, 1995, and on May 15, 1996).

Mr. Hajra has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the four (4) year period beginning July 7, 1997, to exclude himself from:

(1) Contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations);

(2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

Mr. Hajra agreed to request or cooperate in requesting the retraction or correction of those research publications that have not already been corrected or retracted. He also agreed to notify the relevant editors of the affected review articles that the articles cannot be relied upon.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–18453 Filed 7–14–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO–97–16]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Wilma Johnson, CDC Reports Clearance Officer, 1600 Clifton Road, MS–D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Projects

1. *Follow-Up Study of Children With Developmental Disabilities*—New—In the mid-1980s, 10-year-old children were identified as having one or more of five developmental disabilities: mental retardation, cerebral palsy, epilepsy, hearing impairment, or vision impairment. These children were identified (mainly from special education records in the public schools) in the metro-Atlanta area as part of a study to develop surveillance methods for these conditions in school-age children. A follow-up study is proposed to trace, locate, and interview these children, who are now in their early twenties, to assess their status with regard to educational attainment, employment, living arrangements, services received, functional limitations, adaptive behavior, social participation, health, and quality of life. Previous studies (published mostly in the mid-1980s) on the post-secondary school experiences of former recipients of special education services were either limited to one type of impairment (e.g., mild mental retardation) or were restricted to a narrow range of outcomes (e.g., employment and education) or did not incorporate a comparison group of persons who were not in special education. The proposed study is a one-time, in-person interview and includes a contemporaneous comparison group of persons who, at age 10 years, were in regular education classes in the same schools as were the persons with developmental disabilities. A base of 1,608 identified children and 650 comparison persons will be used to find a total of 1,600 who will be interviewed. The data generated from this study will be used to estimate the burden of secondary health conditions, limited social participation, and economic disadvantage among young adults with long-standing developmental impairments. This information will be helpful to efforts aimed at the prevention of various secondary problems in this population. The total cost to respondents is $0.

Respondents	Number of respondents	Number of responses/ respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Initial Location Call	2,258	1	.08	180
Contact Call	1,900	1	.17	323
Scheduling Call	1,600	1	.08	128
Telephone Interview	1,600	1	1	1600
Total				2231

Dated: July 9, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–18498 Filed 7–14–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Task Group Session of the Safety and Occupational Health Study Section, National Institute for Occupational Safety and Health (NIOSH).